Gri Bio, Inc. (GRI)
NASDAQ:GRI
Top Page
GRI Bio
(NASDAQ:GRI)
Select Model
Select Model
Rating:43Neutral
Price Target:
$2.50
▲(792.86% Upside)
Action:ReiteratedDate:03/18/26
The score is held down primarily by weak financial performance (widening losses, negative margins, and elevated cash burn) and bearish technicals (below key moving averages with negative MACD). A low-debt balance sheet and encouraging Phase 2a updates provide partial offsets, but the negative P/E and lack of dividend support keep the overall profile risk-tilted.
Positive Factors
Clinical proof‑of‑concept
Robust Phase 2a molecular and biomarker results for GRI‑0621 provide meaningful proof‑of‑concept that the candidate may act as a disease‑modifying therapy in IPF. This durable clinical signal improves the probability of advancement, strengthens partner/licensing interest, and supports long‑term commercial differentiation versus symptomatic therapies.
Negative Factors
Widening losses / weak profitability
The company remains deeply loss‑making with a roughly 41% net loss margin and widening losses year‑over‑year, undermining internal funding capacity. Persistent negative profitability indicates the operating model has yet to demonstrate scalable margins and forces dependence on external capital to sustain multi‑year clinical programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical proof‑of‑concept
Robust Phase 2a molecular and biomarker results for GRI‑0621 provide meaningful proof‑of‑concept that the candidate may act as a disease‑modifying therapy in IPF. This durable clinical signal improves the probability of advancement, strengthens partner/licensing interest, and supports long‑term commercial differentiation versus symptomatic therapies.
Read all positive factors
GRI Bio (GRI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.32M
Dividend YieldN/A
Average Volume (3M)49.82K
Price to Earnings (P/E)―
Beta (1Y)2.33
Revenue GrowthN/A
EPS Growth98.22%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.39
Shares Outstanding1,445,029
10 Day Avg. Volume40,651
30 Day Avg. Volume49,823
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.11
Price to Sales (P/S)0.00
P/FCF Ratio-0.07
Enterprise Value/Market Cap-2.39
Enterprise Value/Revenue-0.28
Enterprise Value/Gross Profit1.99K
Enterprise Value/Ebitda0.66
Forecast
1Y Price Target
$25.00Price Target Upside8828.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-50.12
Revenue Forecast (FY)N/A
GRI Bio Business Overview & Revenue Model
Company Description
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product ca...
How the Company Makes Money
null...
GRI Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.87M | 0.00 | 22.54M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.00K | -4.00K | -4.00K | -57.00K | -50.00K | -73.00K |
| EBITDA | -11.96M | -11.97M | -8.20M | -10.90M | -2.51M | -9.21M |
| Net Income | -11.96M | -11.96M | -8.21M | -13.04M | -3.22M | -9.30M |
Balance Sheet | ||||||
| Total Assets | 8.67M | 8.67M | 5.74M | 2.96M | 383.00K | 218.00K |
| Cash, Cash Equivalents and Short-Term Investments | 8.23M | 8.23M | 5.03M | 1.81M | 9.00K | 90.00K |
| Total Debt | 71.00K | 71.00K | 119.00K | 14.00K | 673.00K | 3.61M |
| Total Liabilities | 2.66M | 2.66M | 1.71M | 2.70M | 2.01M | 4.94M |
| Stockholders Equity | 6.01M | 6.01M | 4.03M | 259.00K | -1.63M | -4.72M |
Cash Flow | ||||||
| Free Cash Flow | -10.19M | -10.19M | -8.61M | -9.00M | -1.09M | -847.00K |
| Operating Cash Flow | -10.19M | -10.19M | -8.61M | -8.99M | -1.08M | -847.00K |
| Investing Cash Flow | -3.00K | -3.00K | 0.00 | -8.00K | -3.00K | 0.00 |
| Financing Cash Flow | 13.39M | 13.39M | 11.83M | 10.80M | 1.01M | 600.00K |
GRI Bio Technical Analysis
Negative
0.28
Price Trends
3.28
Negative
18.16
Negative
32.47
Negative
Market Momentum
-0.40
Negative
36.02
Neutral
19.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRI, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 2.55, below the 50-day MA of 3.28, and below the 200-day MA of 32.47, indicating a bearish trend. The MACD of -0.40 indicates Negative momentum. The RSI at 36.02 is Neutral, neither overbought nor oversold. The STOCH value of 19.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRI.
GRI Bio Risk Analysis
GRI Bio disclosed 54 risk factors in its most recent earnings report. GRI Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GRI Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $3.32M | ― | -381.74% | ― | ― | 98.22% | |
| ― | $2.51M | -0.17 | -168.95% | ― | ― | 90.27% | |
41 Neutral | $1.99M | ― | -82.17% | ― | -3.27% | 51.83% | |
| ― | $2.31M | -1.82 | -263.57% | ― | -34.58% | 96.41% |
* Healthcare Sector Average
GRI
GRI Bio
2.30
-162.06
-98.60%
OGEN
Oragenics
0.58
-6.44
-91.77%
INM
InMed Pharmaceuticals
0.68
-1.96
-74.20%
KTTA
Pasithea Therapeutics Corp
0.78
-0.54
-41.06%
ONCO
Onconetix
3.22
-42.55
-92.97%
GRI Bio Corporate Events
Business Operations and StrategyPrivate Placements and Financing
GRI Bio Expands At-The-Market Equity Offering Capacity
Neutral
Jan 30, 2026
GRI Bio, Inc. amended its existing at-the-market equity offering program with H.C. Wainwright Co., LLC on January 29, 2026, effective January 28, 2026, significantly increasing the potential size of the offering. The company raised the aggregate ...
Business Operations and StrategyProduct-Related Announcements
GRI Bio reports promising Phase 2a data in IPF
Positive
Jan 28, 2026
On January 28, 2026, GRI Bio reported additional positive data from its recently completed Phase 2a clinical trial of GRI-0621 in idiopathic pulmonary fibrosis, showing that RNA-sequencing gene expression analysis revealed significant modulation o...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
GRI Bio Announces 1-for-28 Reverse Stock Split
Negative
Jan 21, 2026
On January 21, 2026, GRI Bio, Inc. announced that its board and stockholders had approved a 1-for-28 reverse stock split of its common stock, following a special meeting held on January 15, 2026. The reverse split will take legal effect at 4:01 p....
Delistings and Listing ChangesRegulatory Filings and Compliance
GRI Bio Regains Conditional Compliance With Nasdaq Listing Requirements
Neutral
Jan 16, 2026
On January 15, 2026, GRI Bio, Inc. was notified by Nasdaq’s Listing Qualifications Staff that it had conditionally regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies with a market value under $35 million and an...
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder MeetingsStock Split
GRI Bio Shareholders Authorize Reverse Stock Split Plan
Neutral
Jan 15, 2026
On January 15, 2026, GRI Bio, Inc. held a virtual special meeting of stockholders at which shareholders approved an amendment to the company’s certificate of incorporation authorizing a reverse stock split of its common stock at a ratio betw...
Private Placements and FinancingRegulatory Filings and Compliance
GRI Bio Expands At-The-Market Equity Offering Capacity
Neutral
Jan 9, 2026
On January 9, 2026, GRI Bio, Inc. filed a prospectus supplement to increase the maximum amount of common stock it may issue under its at-the-market offering agreement with H.C. Wainwright Co. to an aggregate of $7.38 million in new shares, on top...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
GRI Bio Highlights Positive Phase 2a Data in IPF
Positive
Jan 8, 2026
On January 8, 2026, GRI Bio reported additional positive immune profiling data from its Phase 2a clinical trial of GRI-0621 in idiopathic pulmonary fibrosis, showing inhibition of invariant NKT cells and a shift toward an anti-fibrotic immune prof...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.